Physician profile
Matthew S Simpson
NPI 1518055433
$15,640.90
in general payments reported to CMS, 2019-2025
50 companies · $2,404 in 2025
The $2,404 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,234 · 2020: $1,974 · 2021: $2,528 · 2022: $2,189 · 2023: $2,157 · 2024: $2,155 · 2025: $2,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,715.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,501.35 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,944.36 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,532.17 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,106.21 | 2019-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Lilly USA, LLC | $1,054.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $910.85 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $564.34 | 2019-2024 | Trintellix |
| Astellas Pharma US INC | $561.22 | 2020-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $557.64 | 2021-2024 | Vraylar, Ubrelvy |
| Amgen INC. | $474.33 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $328.56 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $315.62 | 2020-2024 | Nuzyra |
| Sumitomo Pharma America, INC. | $264.24 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $261.38 | 2019-2023 | |
| Amarin Pharma, INC. | $237.34 | 2019-2020 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $225.01 | 2021-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $222.99 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.63 | 2019-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $205.69 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $167.69 | 2019-2021 | |
| Antares Pharma, INC. | $153.01 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceutical Holding Company LTD. | $136.65 | 2022 | |
| Jazz Pharmaceuticals INC. | $131.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $131.53 | 2019-2025 | Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $127.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Daiichi Sankyo INC. | $122.52 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $112.14 | 2021-2023 | Livalo, Seglentis |
| Abbott Laboratories | $93.04 | 2022-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $92.55 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.86 | 2022-2023 | Eliquis |
| Axsome Therapeutics, INC. | $90.09 | 2022-2024 | Sunosi |
| Novartis Pharmaceuticals Corporation | $85.57 | 2019-2024 | |
| Acella Pharmaceuticals, LLC | $74.22 | 2024-2025 | NP Thyroid 60 |
| Teva Pharmaceuticals USA, INC. | $70.90 | 2019-2020 | |
| Genentech USA, INC. | $53.74 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $47.57 | 2025 | Voquezna |
| Radius Health, INC. | $44.91 | 2023-2024 | Tymlos |
| Melinta Therapeutics, LLC | $44.41 | 2019 | |
| Medtronic USA, INC. | $41.15 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $38.53 | 2020-2021 | |
| Tolmar, INC. | $37.63 | 2024-2025 | Jatenzo |
| Halozyme INC | $30.31 | 2023 | |
| Currax Pharmaceuticals LLC | $30.00 | 2024 | Contrave, Onzetra Xsail |
| Sunovion Pharmaceuticals INC. | $28.83 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $18.87 | 2025 | Fanapt |
| Inspire Medical Systems, INC. | $14.52 | 2024 | Inspire |
| Eisai INC. | $14.32 | 2020 | |
| Shire North American Group INC | $14.16 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.10 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $13.68 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.